While saliva‐based biomarkers show promise for detecting AD pathology, including Aβ, tau, pTau isoforms, NfL, GFAP, and lactoferrin, their clinical utility remains unknown, warranting future investigation. This evidence concerns the gene NEFL and Alzheimer disease.